The Evolving Landscape Of Oncology Drug Development

By Louise Scott PhD, Senior Director, Oncology Drug Development

With new cancer cases projected to rise significantly by 2050, the demand for innovative treatments is more urgent than ever. Explore the current landscape of oncology drug development, as well as the surge in clinical trials and the increasing role of small and mid-size biotech companies. Novel drug modalities are emerging to offer alternatives to traditional chemotherapy and radiation, including precision medicine, immuno-oncology, and radiopharmaceuticals. Advancements, such as antibody-drug conjugates (ADCs) and bispecific antibodies (BSABs), leverage new approaches to target cancer cells and harness the body's immune system. In this article, readers will learn how leveraging these targeted approaches allows researchers to move beyond traditional treatments and develop more effective and personalized therapies that can improve patient outcomes.